CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced the presentation of data from a completed clinical study utilizing radiolabeled TM601, demonstrating highly specific tumor uptake of intravenously
For more information, please visit
http://www.businesswire.com/news/home/20090617005022/en